[Recent progress and novel perspectives on obesity pharmacotherapy].
Obesity prevalence has risen dramatically over the past decades, which poses a great number of patients at risk of metabolic and cardiovascular complications. Long-term efficacy of lifestyle modification isolated has shown to be modest which, therefore, urges the need of more aggressive interventions such as adjuvant pharmacotherapy or the more radical surgical approach. Bariatric surgery has proven to date to be the most effective treatment, although it may be associated with nutritional and metabolic complications not yet completely recognized. By contrast, there is limited availability of antiobesity agents currently in the market, as well as historical facts involving the suspension of previously existing medications due to safety concerns. This article aims to present recent data on clinical trials of novel weight-loss drugs with short perspective to enter the market, if approved by the regulatory agencies. This review will discuss the efficacy and safety of these compounds, which include lorcaserin (selective serotonin 5-HT2c agonist), tesofensine (triple monoamine reuptake inhibitor), liraglutide (GLP-1 analogue) and cetilistat (gastrointestinal lipase inhibitor), as well as the combination therapies of bupropion/naltrexone, bupropion/zonisamide, phentermine/topiramate and pramlintide/metreleptin.
Faria
André M
AM
Hospital das Clínicas, Universidade de São Paulo, SP, Brasil.
Mancini
Marcio C
MC
Melo
Maria Edna de
ME
Cercato
Cintia
C
Halpern
Alfredo
A
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D050110:Bariatric Surgery; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D012307:Risk Factors
D019440:Anti-Obesity Agents